Cerus Corporation (CERS) reported second-quarter 2026 total revenue of $63.3 million, up 5% year over year, and product revenue of $57.4 million, up 10%. Net loss attributable to Cerus was $2.9 million, or $0.01 per basic and diluted share, compared with a $5.7 million loss, or $0.03 per share, a year earlier.
The company raised the lower end of its 2026 product revenue guidance to a range of $229 million to $231 million and increased its IFC sales outlook to $23 million to $25 million. Cash, cash equivalents and short-term investments were $56.3 million at June 30, 2026.
- Second-quarter product revenue was $57.4 million, compared with $52.4 million in the prior-year period.
- Government contract revenue was $5.9 million, compared with $7.7 million a year earlier.
- Second-quarter U.S. IFC sales totaled $6.7 million, up from $5.6 million in the prior-year period.
- Total operating expenses were $37.3 million, down 7% year over year.
- Cerus submitted a PMA for its INT200 illuminator to the FDA, with a regulatory decision anticipated in early 2027.
- The company expanded its BARDA collaboration, increasing the total potential value of the 2024 contract to $270.5 million.
$CERS Insider Trading Activity
$CERS insiders have traded $CERS stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $CERS stock by insiders over the last 6 months:
- WILLIAM MARINER GREENMAN (President and CEO) has made 0 purchases and 3 sales selling 627,863 shares for an estimated $1,198,764.
- VIVEK K JAYARAMAN (Chief Executive Officer) has made 0 purchases and 6 sales selling 291,653 shares for an estimated $619,469.
- KEVIN DENNIS GREEN (Chief Financial Officer) has made 0 purchases and 4 sales selling 244,241 shares for an estimated $480,117.
- RICHARD J BENJAMIN (Chief Medical Officer) has made 0 purchases and 4 sales selling 227,634 shares for an estimated $419,541.
- CHRYSTAL JENSEN (Chief Legal Officer) has made 0 purchases and 2 sales selling 55,174 shares for an estimated $133,457.
- ERIC BJERKHOLT sold 20,454 shares for an estimated $53,180
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CERS Hedge Fund Activity
We have seen 79 institutional investors add shares of $CERS stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 6,753,700 shares (+168.8%) to their portfolio in Q1 2026, for an estimated $12,291,734
- WASATCH ADVISORS LP removed 1,897,237 shares (-35.9%) from their portfolio in Q2 2026, for an estimated $5,539,932
- MORGAN STANLEY removed 1,114,173 shares (-57.4%) from their portfolio in Q1 2026, for an estimated $2,027,794
- DRIEHAUS CAPITAL MANAGEMENT LLC added 961,606 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,750,122
- UBS GROUP AG added 956,851 shares (+83.8%) to their portfolio in Q1 2026, for an estimated $1,741,468
- CITADEL ADVISORS LLC removed 945,020 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,719,936
- ASSENAGON ASSET MANAGEMENT S.A. removed 936,043 shares (-74.8%) from their portfolio in Q2 2026, for an estimated $2,733,245
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
